Evidence map›Paper›PMID 40918131›Full record

ReviewFrontiers in immunology2025

Kaempferol as a multifaceted immunomodulator: implications for inflammation, autoimmunity, and cancer.

Han Dong, Ge Song, Zhe Wang, Xue Wu, Qi Wang, Yue-Hui Wang

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Foods (Basel, Switzerland) · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. A systems pharmacology-basedFrontiers in veterinary science · 2026
    Article
  13. [Kaempferol in improving chemotherapy-induced myelosuppression: A scoping review].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Han DongDepartment of Geriatrics, Jilin Geriatrics Clinical Research Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Ge SongDepartment of Gerontology, The Second Medical Center & National Clinical Research Center of Geriatric Diseases, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
Zhe WangDepartment of Geriatrics, Jilin Geriatrics Clinical Research Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Xue WuDepartment of Geriatrics, Jilin Geriatrics Clinical Research Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Qi WangDepartment of Geriatrics, Jilin Geriatrics Clinical Research Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Yue-Hui WangDepartment of Geriatrics, Jilin Geriatrics Clinical Research Center, The First Hospital of Jilin University, Changchun, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kaempferol (KMF) is a dietary flavonoid exhibiting profound immunomodulatory effects across multiple immune cell populations. This review synthesizes current insights into how KMF regulates diverse immune cell populations and its therapeutic potential in inflammatory and immune-related disorders. KMF exhibits multifaceted effects on T cells. It inhibits T cell activation via suppressing various signaling pathways and calcineurin. Additionally, it regulates T cell subset balance through the modulation of different transcription factors. In natural killer (NK) cells, KMF enhances proliferation and cytotoxicity. This effect is partly mediated by gut microbiota modulation, which further boosts anti-tumor immunity. For dendritic cells (DCs), KMF shows context-dependent effects. It can promote adaptive immunity in some settings, while in inflammatory contexts, it suppresses DC maturation and cytokine secretion. KMF reduces neutrophil infiltration and the formation of neutrophil extracellular traps (NETs). It also alleviates eosinophil-driven allergic inflammation and blocks mast cell degranulation. Regarding macrophages, KMF shifts polarization from pro-inflammatory M1 to anti-inflammatory M2 phenotypes in metabolic and fibrotic models. In cancer, however, it inhibits the polarization of tumor-associated M2 macrophages. Overall, KMF modulates multiple immune cell types and signaling pathways, positioning it as a promising candidate for treating autoimmune, inflammatory, and neoplastic diseases. Further translational research is warranted to explore its clinical utility and optimize delivery strategies.

Indexed as

AutoimmunityImmunomodulating AgentsInflammationKaempferolsNeoplasmsAnimalsHumansSignal TransductionImmunomodulating AgentskaempferolKaempferolsdendrite cellsgranulocytesKaempferolmacrophagesmodulationnatural killer cellsT cells

Identifiers

PMID40918131
PMCPMC12408509

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.